Shanghai Nianxing Industrial Co., Ltd
China
Product Name: Palmitic acid
Price: Check
Purity: 98.0%
Stocking Period: 10 Day
Contact: Yang
Email: sales@echemcloud.com

Henan Tianfu Chemical Co., Ltd.
China
Product Name: Sacubitril/Valsartan Trisodium Salt
Price: $Inquiry/1kg $Inquiry/25kg $Inquiry/1000kg $Inquiry/10ton
Purity: 99.0%
Stocking Period: Inquiry
Contact: Anson
Email: info@tianfuchem.com

936623-90-4

936623-90-4 structure

936623-90-4 structure

Name: Sacubitril/valsartan (LCZ696)
Chemical Name: lcz696
CAS Number: 936623-90-4
Molecular Formula: C₄₈H₆₀N₆Na₃O_10.5
Molecular Weight: 957.99
Catalog: Biochemical Inhibitor Endocrinology & Hormones RAAS inhibitor
Create Date: 2016-09-20 01:44:19
Modify Date: 2026-06-30 16:48:29
LCZ696 is a dual angiotensin II receptor and neprilysin inhibitor.

Name	lcz696
Synonyms	Valstan-Sacubitril sodium Radix isatidis polysacchides LCZ696 ENTRESTO TM L-Valine, N-(1-oxopentyl)-N-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-, compd. with α-ethyl (αR,γS)-γ-[(3-carboxy-1-oxopropyl)amino]-α-methyl[1,1'-biphenyl]-4-pentanoate, sodium salt, hydrate (2:2:6:5) Valstan/sacubitril Sacubitril Valstan trisodium hydrate Sacubitril-Valstan complex Sakubitrexovalstan LCZ696;LCZ Sacubitril/Valstan, 10 mM in DMSO Cocrystal of Sacubitril and Valstan Sodium 4-{[(2S,4R)-1-(4-biphenylyl)-5-ethoxy-4-methyl-5-oxo-2-pentanyl]amino}-4-oxobutanoate (2S)-3-methyl-2-(pentanoyl{[2'-(tetrazol-1-id-5-yl)-4-biphenylyl]methyl}amino)butanoate hydrate (6:2:2:5) LCZ696 Entresto LCA696 Sacubatril/Valstan Sacubitril Valstan cocrystal (LCZ696) Secubitril Sodium (S)-2-(N-((2'-(2H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)pentanamido)-3-methylbutanoic acid 4-(((2S,4R)-1-([1,1'-biphenyl]-4-yl)-5-ethoxy-4-methyl-5-oxopentan-2-yl)amino)-4-oxobutanoic acid hydrate(3:1:1:2.5) LCZ696（valstan + sacubitril）Sodium impurity 58 2.5 Hydrate 3-(1-Biphenyl-4-ylMethyl-3-ethoxycarbonyl-1-butylcarbaMoyl)propionate-3'-Methyl-2'-(pentanoyl(2'-(tetrazol-5-ylate)biphenyl-4'-ylMethyl)aMino)butyrate 3-(1-Biphenyl-4-ylMethyl-3-ethoxycbonyl-1-butylcbaMoyl)propionate-3'-Methyl-2'-(pentanoyl(2'-(tetrazol-5-ylate)biphenyl-4'-ylMethyl)amino)butyrate Sacubitril-Valstan trisodium salt hydrate Valstan/Sacubitril (1:1) trisodium [3-((1S,3R)-1-biphenyl-4-ylmethyl-3-ethoxycarbonyl-1-butylcarbamoyl)propionate-(S)-3-methyl-2-(pentanoyl{2”-(tetrazol-5-ylate)biphenyl-4-ylmethyl}amino)butyrate] hemipentahydrate Entresto（LCZ696） Sacubitril/Valstan Trisodium Salt Entresto N-(1-oxopentyl)-N-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-L-valine, compd. with α-ethyl (αR,γS)-γ-[(3-cboxy-1-oxopropyl)amino]-α-methyl[1,1'-biphenyl]-4-pentanoate, sodium salt, hydrate LCZ696（valstan + sacubitril）Sodium Impurity 2.5 Hydrate Linagliptin Impurity CD10121 LCZ696 valstan + sacubitril Sodium impurity 58 Sand libry will be LCZ696 (Valsta + Sacubitril) Entresto (sacubitril/valstan) LCZ696 Sacubitril-Valstan Trisodium Salt 2.5H2O 4-[[(2S,4R)-5-ethoxy-4-methyl-5-oxo-1-(4-phenylphenyl)pentan-2-yl]amino]-4-oxobutanoate Valsartan LCZ 696 LCZ696(Sacubitril/Valstan) LCZ696 (Valstan) Sacubitril valstan sodium hydrate sodium (S)-5-(4'-((N-(1-cboxylato-2-methylpropyl)pentanamido)methyl)-[1,1'-biphenyl]-2-yl)tetrazol-1-ide 4-(((2S,4R)-1-([1,1'-biphenyl]-4-yl)-5-ethoxy-4-methyl-5-oxopentan-2-yl)amino)-4-oxobutanoate LCZ696 (936-4) LCZ696 (Shakubi Qusstan) Sacubatrava valstan [(C24H29N5O3).(C24H29NO5).2.5(H2O).3Na] Sacubitril-Valstan Trisodium Salt 2.5hydrate Sacubitril mixture with Valstan 1H-Isoindole-1,3(2H)-dione,2-[2-(3,4-dihydro-2,2,4-trimethyl-1(2H)-quinolinyl)-5-oxoethyl] (S)-2-(N-((2'-(1H-Tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)hexanamido)-3-methylbutanoic acid lcz696/Valstan/sacubitril trisodium 3-((1S,3R)-1-(biphenyl-4-ylmethyl)-3-(ethoxycarbonyl)butylcarbamoyl)propionate (S)-3-methyl-2-(pentanoyl-(2-(tetrazol-1-at-5-yl)biphenyl-4'-ylmethyl)amino)butyrate hemipentahydrate LCZ696 //BP Valstan-sacubitril(LCZ696) LCZ696 interMediate Sacubatro valstan Sacubitril Valsatran Co Crystal In-House Sacubitril/Valstan LCZ API LZC696 Sacubitril Valstan (LCZ696) Entresto,Valstan/sacubitril

Description	LCZ696 is a dual angiotensin II receptor and neprilysin inhibitor.
Related Catalog	Signaling Pathways >> GPCR/G Protein >> Angiotensin Receptor Signaling Pathways >> Metabolic Enzyme/Protease >> Neprilysin Research Areas >> Cardiovascular Disease
In Vitro	LCZ696 is a single molecule that is comprised of molecular moieties of valsartan, an ARB, and AHU377, a neprilysin inhibitor (1:1 ratio)[1].
In Vivo	LCZ696 exerts a blood pressure lowering effect. Blood pressure reduction by LCZ696 is associated with a significant increase in urinary sodium excretion and sympathetic activity suppression. LCZ696 significantly ameliorates cardiac hypertrophy and inflammation, coronary arterial remodeling, and vascular endothelial dysfunction in high-salt loaded SHRcp compared with valsartan[1]. The neprilysin inhibitor component of LCZ696, LBQ657, inhibits hypertrophy but not fibrosis. The angiotensin receptor blocker component of LCZ696, valsartan inhibits both hypertrophy and fibrosis. Dual valsartan+LBQ augment the inhibitory effects of valsartan and the highest doses completely abrogate angiotensin II-mediated effects[2]. Pre-treatment with LCZ696 reduces the ischemic area. The decrease in cerebral blood flow in the peripheral region of the ischemic area is significantly attenuated by pre-treatment with LCZ696. LCZ696 pre-treatment significantly decreases the increase of superoxide anion production in the cortex on the ischemic side[3].
Animal Admin	Rats: LCZ696 or valsartan is orally administered as a powder in gelatin mini-capsules at the beginning of the dark period once daily. The vehicle group rats are given empty capsules. Miniature telemetry devices are implanted into 12 or 13-week-old SHRs. BP and heart rate variability, low frequency power of systolic BP, and spontaneous baroreceptor reflex gain are monitored during the dark and light periods. The SHRs are divided into 3 groups at 16 weeks of age: (i) vehicle, (ii) LCZ696, and (iii) valsartan. The dose of LCZ696 and valsartan is 20 and 10mg/kg/day from 16 to 18 weeks of age, respectively, and 60 and 30mg/kg/day from 18 to 23 weeks of age, respectively. At 21 weeks of age, the SHR diet is switched to a low-salt diet from a high-salt diet[1]. Mice: Mice are treated with VAL (3 mg/kg per day) or LCZ696 (6 mg/kg per day) orally as powder in gelatin mini-capsules daily for 2 weeks before MCA occlusion. Body weight is measured after VAL or LCZ696 pre-treatment for 2 weeks. Systolic blood pressure, diastolic blood pressure and heart rate are measured by telemetry at 10 weeks of age[3].
References	[1]. Huo H, et al. Erastin Disrupts Mitochondrial Permeability Transition Pore (mPTP) and Induces Apoptotic Death of Colorectal Cancer Cells. PLoS One. 2016 May 12;11(5):e0154605. [2]. von Lueder TG, et al. Angiotensin receptor neprilysin inhibitor LCZ696 attenuates cardiac remodeling and dysfunction after myocardial infarction by reducing cardiac fibrosis and hypertrophy. Circ Heart Fail. 2015 Jan;8(1):71-8. [3]. Bai HY, et al. Pre-treatment with LCZ696, an orally active angiotensin receptor neprilysin inhibitor, prevents ischemic brain damage. Eur J Pharmacol. 2015 Sep 5;762:293-8.

Molecular Formula	C₄₈H₆₀N₆Na₃O_10.5
Molecular Weight	957.99
PSA	207.53000
LogP	5.34730
Storage condition	2-8°C

The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.